Canada's vaccine advisory committee says it's possible to safely give a second dose of the COVID-19 vaccine to people who experienced severe allergic reactions to their first shot.
The National Advisory Committee on Immunization says there have been cases of severe anaphylactic reactions to mRNA vaccines documented in Canada after their first dose.
Studies show the reaction often is not repeated with the second dose, however, and the second dose was tell tolerated with either no reactions or just mild ones.The committee encourages people who had an allergic reaction to a mRNA vaccine -- those produced by Pfizer-BioNTech and Moderna -- to see an allergist before seeking the next dose.
The committee also released new advice about waiting longer for a second dose, suggesting that a longer gap between shots is more effective. NACI now suggests waiting eight weeks between mRNA COVID-19 vaccines and at least eight weeks between shots of AstraZeneca.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Businesses risk 'double whammy' with COVID-19 benefits ending, economist saysBusinesses risk a 'double whammy' of potential labour shortages and a decline in consumer spending due to COVID-19 benefits ending Saturday, an economist says.
Read more »
Ontario can control COVID-19 with continued health measures, science table saysModelling shows that if there is no change in policy or people’s behaviours, cases will continue to decline, while some increase in social contacts will keep cases stable
Read more »
Canada considers what to do with millions of unused COVID-19 vaccine dosesCanada must decide what to do with millions of unused COVID-19 vaccine doses now that officials have confirmed they won't be needed to vaccinate children.
Read more »
Ontario reports 492 new COVID-19 cases, 12 more deaths
Read more »
Pfizer says COVID-19 vaccine more than 90 per cent effective in kidsKid-size doses of Pfizer's COVID-19 vaccine appear safe and nearly 91 per cent effective at preventing symptomatic infections in 5- to 11-year-olds, according to study details released Friday as the U.S. considers opening vaccinations to that age group.
Read more »